CD4+ T cells are sufficient to elicit allograft rejection and major histocompatibility complex class I molecule is required to induce recurrent autoimmune diabetes after pancreas transplantation in mice

Transplantation

Volumn 85, Issue 8, 2008, Pages 1205-1211

  Xiang, Zhidan ^a   Ma, Lian Li ^a   Manicassamy, Santhakumar ^b   Ganesh, Balaji B ^b   Williams, Phillip ^a   Chari, Ravi ^a   Chong, Anita ^c   Yin, Deng Ping ^a,d  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d VANDERBILT UNIVERSITY   (United States)

Author keywords

Allograft rejection; Autoimmune response; MHC; Mice; Pancreas transplantation; T cells

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL TRANSFER; CONTROLLED STUDY; DIABETES MELLITUS; GRAFT REJECTION; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; SPLEEN CELL;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DIABETES MELLITUS, TYPE 1; GRAFT REJECTION; HISTOCOMPATIBILITY ANTIGENS CLASS I; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; PANCREAS TRANSPLANTATION; RECURRENCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 42549123671     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31816b70bf     Document Type: Article

References (34)

1. Lakey JR, Mirbolooki M, Shapiro AM. Current status of clinical islet cell transplantation. Methods Mol Biol 2006; 333: 47.
2. Yin D, Ding JW, Shen J, et al. Liver ischemia contributes to early islet failure following intraportal transplantation: Benefits of liver ischemic-preconditioning. Am J Transplant 2006; 6: 60.
3. Kandaswamy R, Sutherland DE. Pancreas versus islet transplantation in diabetes mellitus: How to allocate deceased donor pancreata. Transplant Proc 2006; 38: 365.
4. Mottram PL, Murray-Segal LJ, Han W, et al. Transgenic anti-CD4 monoclonal antibody secretion by mouse segmental pancreas allografts promotes long term survival. Transpl Immunol 2000; 8: 203.
5. Makhlouf L, Grey ST, Dong V, et al. Depleting anti-CD4 monoclonal antibody cures new-onset diabetes, prevents recurrent autoimmune diabetes, and delays allograft rejection in nonobese diabetic mice. Transplantation 2004; 77: 990.
6. Parish NM, Hutchings PR, Waldmann H, et al. Tolerance to IDDM induced by CD4 antibodies in nonobese diabetic mice is reversed by cyclophosphamide. Diabetes 1993; 42: 1601.
7. Alters SE, Shizuru JA, Ackerman J, et al. Anti-CD4 mediates clonal anergy during transplantation tolerance induction. J Exp Med 1991; 173: 491.
8. Kleindienst P, Wiethe C, Lutz MB, et al. Simultaneous induction of CD4T cell tolerance and CD8T cell immunity by semimature dendritic cells. J Immunol 2005; 174: 3941.
9. Bendelac A, Carnaud C, Boitard C, et al. Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt-2+ T cells. J Exp Med 1987; 166: 823.
10. Prange S, Zucker P, Jevnikar AM, et al. Transplanted MHC class I-deficient nonobese diabetic mouse islets are protected from autoimmune injury in diabetic nonobese recipients. Transplantation 2001; 71: 982.
11. Young HY, Zucker P, Flavell RA, et al. Characterization of the role of major histocompatibility complex in type 1 diabetes recurrence after islet transplantation. Transplantation 2004; 78: 509.
12. Markmann JF, Bassiri H, Desai NM, et al. Indefinite survival of MHC class I-deficient murine pancreatic islet allografts. Transplantation 1992; 54: 1085.
13. Markmann JF, Barker CF, Lo D, et al. Islet endocrine cell MHC antigen expression in allograft rejection. Transplant Proc 1990; 22: 847.
14. Sumida T, Furukawa M, Sakamoto A, et al. Prevention of insulitis and diabetes in beta 2-microglobulin-deficient non-obese diabetic mice. Int Immunol 1994; 6: 1445.
15. Prochazka M, Serreze DV, Frankel WN, et al. NOR/Lt mice: MHC-matched diabetes-resistant control strain for NOD mice. Diabetes 1992; 41: 98.
16. Yin DP, Sankary HN, Ma LL, et al. Lewis rat pancreas, but not cardiac xenografts, are resistant to anti-gal antibody mediated hyperacute rejection. Transplantation 2001; 71: 1385.
17. Mandel TE, Koulmanda M, Bacelj A. Fetal pancreas transplantation in non-obese diabetic (NOD) mice. A comparison of iso-, allo- and xenografts. Horm Metab Res Suppl 1990; 25: 166.
18. Molano RD, Berney T, Li H, et al. Prolonged islet graft survival in NOD mice by blockade of the CD40-CD154 pathway of T-cell costimulation. Diabetes 2001; 50: 270.
19. Yin DP, Ma LL, Sankary HN, et al. Role of CD4+ and CD8+ T cells in the rejection of concordant pancreas xenografts. Transplantation 2002; 74: 1236.
20. Krieger NR, Yin DP, Fathman CG. CD4+ but not CD8+ cells are essential for allorejection. J Exp Med 1996; 184: 2013.
21. Yin D, Ma L, Zeng H, et al. Allograft tolerance induced by intact active bone co-transplantation and anti-CD40L monoclonal antibody therapy. Transplantation 2002; 74: 345.
22. Shen J, Chong AS, Xiao F, et al. Histological characterization and pharmacological control of chronic rejection in xenogeneic and allogeneic heart transplantation. Transplantation 1998; 66: 692.
23. Delovitch TL, Singh B. The nonobese diabetic mouse as a model of autoimmune diabetes: Immune dysregulation gets the NOD. Immunity 1997; 7: 727.
24. Kupfer TCM, Pham C, Gill R. MHC-mismatched islet allografts are vulnerable to autoimmune recognition in vivo. J Immunol 2005; 175: 2309.
25. Watschinger B. How T cells recognize alloantigen: Evidence for two pathways of allorecognition. Nephrol Dial Transplant 1995; 10: 1556.
26. Rice JC, Bucy RP. Differences in the degree of depletion, rate of recovery, and the preferential elimination of naive CD4+ T cells by anti-CD4 monoclonal antibody (GK1.5) in young and aged mice. J Immunol 1995; 154: 6644.
27. Thivolet C, Abou-Amara S, Martin X, et al. Serological markers of recurrent beta cell destruction in diabetic patients undergoing pancreatic transplantation. Transplantation 2000; 69: 99.
28. Pearson T, Markees TG, Wicker LS, et al. NOD congenic mice genetically protected from autoimmune diabetes remain resistant to transplantation tolerance induction. Diabetes 2003; 52: 321.
29. Pearson T, Weiser P, Markees TG, et al. Islet allograft survival induced by costimulation blockade in NOD mice is controlled by allelic variants of Idd3. Diabetes 2004; 53: 1972.
30. Makhlouf L, Kishimoto K, Smith RN, et al. The role of autoimmunity in islet allograft destruction: Major histocompatibility complex class II matching is necessary for autoimmune destruction of allogeneic islet transplants after T-cell costimulatory blockade. Diabetes 2002; 51: 3202.
31. Koller BH, Marrack P, Kappler JW, et al. Normal development of mice deficient in beta 2M, MHC class I proteins, and CD8+ T cells. Science 1990; 248: 1227.
32. Hoglund P, Ohlen C, Carbone E, et al. Recognition of beta 2-microglobulin-negative (beta 2m-) T-cell blasts by natural killer cells from normal but not from beta 2m- mice: Nonresponsiveness controlled by beta 2m- bone marrow in chimeric mice. Proc Natl Acad Sci U S A 1991; 88: 10332.
33. Mora C, Wong FS, Chang CH, et al. Pancreatic infiltration but not diabetes occurs in the relative absence of MHC class II-restricted CD4 T cells: Studies using NOD/CIITA-deficient mice. J Immunol 1999; 162: 4576.
34. von Herrath MG, Coon B, Lewicki H, et al. In vivo treatment with a MHCclass I-restricted blocking peptide can prevent virus-induced autoimmune diabetes. J Immunol 1998; 161: 5087.